Sai Parenteral’s IPO Description – Sai Parenteral’s is a diversified pharmaceutical formulations player with integrated capabilities across research, development, and manufacturing, operating through two core verticals: Branded Generic Formulations and Contract Development and Manufacturing Organisation …

We have conducted a deep analysis of the GSP Crop Science RHP and financial disclosures. While you may see the headline growth and improved margins as a compelling story, our GSP Crop IPO analysis reveals …

Speciality Medicines IPO Description – Speciality Medicines is a leading pharmaceutical company engaged in the marketing and distribution of specialty pharmaceutical products, including high-cost oral and injectable medications for complex and chronic medical conditions. The company …

Jagsonpal Pharmaceuticals Buyback Record Date is not finalized.  Jagsonpal Pharmaceuticals is a pharmaceutical company engaged in the manufacturing and marketing of branded generic formulations across multiple therapeutic segments. Jagsonpal primarily focuses on the domestic formulations …

If you’ve been tracking IPO market, this news is critically important for you. On 13 March 2026, the government of India officially updated the rules for Initial Public Offerings (IPOs) to make it easier for …

The Securities and Exchange Board of India (SEBI) gave observation letters to three companies during the second week of March 2026. Conversely, two companies had their offer documents either withdrawn or returned by the regulator. …